Cerenome Secures Up to $20M Royalty-Based Financing, Extends Runway to 2028
CNSY is trading near its 52-week low of $2.489 (8.1% above the low).
Summary
Cerenome announced a senior secured financing facility of up to $20 million with 3i, LP, featuring royalty-based repayments. The company received an initial tranche at closing, with additional tranches contingent on milestones. Management states the facility is minimally dilutive and, combined with existing cash and forecasted CNSide sales, extends the cash runway into 2028. This follows the Q2 10-Q disclosing a $9.0M net loss and going concern doubt, making this financing a critical liquidity event. The royalty structure aligns repayment with future revenue, reducing immediate equity dilution but creating ongoing obligations. Watch for the 8-K filing with full terms and milestone details.
Updates
· SEC 8-K — The 8-K details the $21.3M senior secured convertible note financing with 3i, LP: $3.19M initial notes, $2.13M second notes, and $15.96M additional notes, with an initial closing expected September 10, 2026. Initial notes convert at $2.74 per share with a $0.50 floor, and CNSide will pay a 2.5% quarterly royalty capped at 2.5% of outstanding note balance.
At the time of this announcement, CNSY was trading at $2.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $2.49 to $23.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.